Anti-Trop-2 ADC Combination Therapy for TNBC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating triple-negative breast cancer (TNBC) with anti-Trop-2 antibody-drug conjugates (ADCs) and microtubule or PARP inhibitors are limited in efficacy, particularly in cases resistant to standard therapies, and there is a need for more effective preparation and administration strategies.
Innovation Solution
Combination therapy using an anti-Trop-2 ADC, such as sacituzumab govitecan, conjugated with chemotherapeutic agents like SN-38, in combination with microtubule inhibitors or PARP inhibitors, optimized for dosages and schedules to enhance therapeutic effect, particularly for TNBC and other Trop-2-expressing cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anti-cancer therapies are used to treat TNBC, then treatment is administered with conventional dosages, but the efficacy is limited and tumors remain resistant
Solution Approach 1:
The patent combines anti-Trop-2 ADC with microtubule inhibitors or PARP inhibitors in a multi-agent regimen. This merging of multiple therapeutic mechanisms targets different pathways simultaneously, overcoming tumor resistance that developed against single-agent therapies and improving overall treatment efficacy in TNBC patients
Solution Approach 2:
The patent implements specific optimized dosing schedules and dosage levels for each agent in the combination regimen. By carefully adjusting these parameters - including sequential vs. concurrent administration timing and specific mg/kg dosages - the treatment maximizes synergistic effects while managing toxicity, thereby improving reliability of treatment outcomes
2Reliability
If combination therapy with multiple agents is used, then therapeutic efficacy is enhanced through synergistic effects, but treatment complexity and dosing schedule requirements increase
Solution Approach 1:
The patent employs pre-specified, optimized dosing schedules that are determined before treatment begins. These predetermined protocols - including specific timing intervals between agents and fixed dosage relationships - simplify clinical implementation by removing the need for real-time complex calculations, thereby reducing operational complexity while maintaining synergistic efficacy
Solution Approach 2:
The anti-Trop-2 ADC serves as a targeted delivery vehicle that mediates the combination therapy approach. By conjugating cytotoxic agents to an antibody that specifically binds Trop-2 on tumor cells, the system provides targeted delivery that enhances local efficacy while allowing for optimized dosing that balances the complexity of multi-agent therapy with simplified administration protocols
3Productivity
If higher dosages are administered to overcome resistance, then tumor shrinkage is improved, but toxicity and side effects increase
Solution Approach 1:
The anti-Trop-2 ADC component provides localized delivery of cytotoxic agents directly to Trop-2-expressing tumor cells. This targeted approach concentrates the therapeutic effect at the disease site, achieving tumor shrinkage with lower systemic doses and thereby reducing overall toxicity compared to non-targeted high-dose chemotherapy
Solution Approach 2:
The patent employs dynamic, optimized dosing schedules that adjust the timing and dosage of each agent based on their pharmacokinetic and pharmacodynamic properties. This dynamic approach - including sequential administration and specific dosage intervals - maximizes tumor cell kill while allowing normal tissues time to recover, thereby improving the therapeutic window and reducing cumulative toxicity
Data Source
AI summary
The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and/or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.